For instance, the driver mutation of each subtype, such as von Hippel-Lindau (VHL), PBRM1, and BRCA-1 associated tumor protein 1 (BAP1) in ccRCC; MET and fumarate hydratase (FH) in pRCC; and phosphatase and tensin homolog (PTEN) or TP53 in chrRCC; as well as the mutations related to prognosis, such as BAP1, PBRM1, or SET domain-containing 2 (SETD2) in ccRCC and cyclin-dependent kinase inhibitor 2A (CDKN2A) in pRCC have been identified in numerous NGS studies [7]. This evidence concerns the gene VHL and nonpapillary renal cell carcinoma.